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Abstract
Background: The aim of the research was to separate the distant metastasis (DM) enhancing effect due to breast
tumour removal from that due to surgical manoeuvre by itself.
Methods: DM dynamics following surgery for ipsilateral breast tumour recurrence (IBTR), contralateral breast cancer
(CBC) and delayed reconstruction (REC), which was performed after the original breast cancer surgical removal, was
analysed. A total of 338 patients with IBTR, 239 with CBC and 312 with REC were studied.
Results: The DM dynamics following IBTR, CBC and REC, when assessed with time origin at their surgical treatment,
is similar to the analogous pattern following primary tumour removal, with a first major peak at about 18 months
and a second lower one at about 5 years from surgery. The time span between primary tumour removal and the
second surgery is influential on DM risk levels for IBTR and CBC patients, not for REC patients.
Conclusions: The role of breast tumour removal is different from the role of surgery by itself. Our findings suggest
that the major effect of reconstructive surgery is microscopic metastasis acceleration, while breast tumour surgical
removal (either primary or IBTR or CBC) involves both tumour homeostasis interruption and microscopic metastasis
growth acceleration. The removal of a breast tumour would eliminate its homeostatic restrains on metastatic foci,
thus allowing metastasis development, which, in turn, would be supported by the forwarding action of the
mechanisms triggered by the surgical wounding.
Keywords: Breast cancer, Recurrence dynamics, Metastasis development, Second surgery, Tumour homeostasis,
Surgery-related metastasis acceleration
Background
In the middle of the nineteenth century, the arguments
set out by Virchow, who suggested that the disease starts
as a single focus within the breast, then migrates to the
axillary lymph nodes and ultimately to distant organs,
supported the Halsted operation that was adopted as the
default therapy worldwide [1]. However, among resected
patients, 30% of node-negative and 75% of node-positive
women still developed distant metastases and succumbed
[2]. The failure of mastectomy and other more aggressive
operations to cure patients and, moreover, novel
biology-based assumptions on the disease course [3] sug-
gesting that the extent of local treatment does not affect
survival supported a reduction of the extent of surgery.
Additionally, clinical investigations and mathematical
modelling advocated that surgical resection might not al-
ways be beneficial [4, 5] providing evidence that, while it
favourably modifies the natural history of breast cancer
for the majority of patients, it may also hasten the meta-
static development for a number of them, by triggering
growth of occult tumour deposits. The concepts under-
lying this new model extended to the clinical level the re-
sults of a protracted history of investigations lasting more
than a century [6].
Helpful hints about the new model were achieved
from analyses of post-resection recurrence dynamics in
early breast cancer patients undergoing potentially
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curative removal of the primary tumour [7, 8]. A model
assuming post-surgery acceleration of disease progres-
sion by a burst of growth in previously dormant micro-
metastases appeared to best fit the clinical data. Similar
findings were observed in non-small cell lung cancer [9].
While this acceleration apparently occurs at the time of
local treatment, it is still not deciphered whether this ef-
fect can be ascribed to primary tumour removal (e.g. to
removal of inhibitory factors) or to the surgical
manoeuvre per se (e.g. CTC release, immune suppres-
sion and pro-angiogenic stimulus of wounding) or to
both. This differentiation is important as it may open a
window to new therapeutic approaches.
Clues about this subject may be detected by the ana-
lysis of the recurrence dynamics in patients who
undergo subsequent breast surgical manoeuvres during
the follow-up of the disease in addition to primary
tumour surgical removal. Patients undergoing conserva-
tive surgery for their primary tumour may experience ip-
silateral breast tumour recurrence (IBTR), and others
may be diagnosed contralateral breast cancer (CBC)
whatever the surgical approach for the primary tumour
has been. Moreover, some patients undergoing mastec-
tomy as the first surgical treatment call for breast recon-
struction (REC) and undergo aesthetical surgery. We
hypothesized different metastatic recurrence dynamics
associated with the different surgical procedures due to
the clinical presence (IBTR and CBC) or absence (REC)
of a tumour reservoir in the breast. Therefore, we report
here findings from the analysis of distant metastasis
(DM) dynamics following IBTR, CBC and REC, which
was carried out with the aim of unravelling the different
roles, if any, of the two possible factors, i.e. breast
tumour removal and surgical manoeuvre by itself.
Patients and methods
At the National Cancer Institute of Milan, three ran-
domized clinical trials have been carried out in the past,
investigating the role of different surgical approaches for
primary tumour removal. Moreover, since preliminary
results of the first trial on the breast-conserving treat-
ment for early breast cancer, which provided evidence
that conservative surgery plus chest wall radiotherapy
was comparable to more aggressive resections [10], pa-
tients received breast-conserving treatment as routine
practice outside randomized clinical trials (out-trial
patients). All axillary node-positive (N+) patients were
offered systemic adjuvant treatment with cyclophospha-
mide + methotrexate + fluorouracil (CMF) or CMF plus
doxorubicin, while no further post-surgical systemic
treatment was recommended to axillary node-negative
(N−) patients. Adjuvant hormone therapy was not uti-
lized within the randomized clinical trials and seldom
employed for out-trial patients, as it was not considered
mandatory at that time. Two other randomized clinical
trials were accomplished on patients who, following
mastectomy or breast-conserving treatment, were found
to be axillary node positive (N+). Patients with one to
three positive axillary lymph nodes were randomly allo-
cated to receive either 12 courses of CMF or 8 courses
of the same regimen followed by 4 courses of doxorubi-
cin, while patients with > 3 positive axillary nodes were
randomized to receive either four courses of doxorubicin
followed by 8 courses of CMF or 2 courses of CMF and
1 course of doxorubicin for a total of 12 courses. All
clinical data from patients enrolled into the reported
clinical trials or treated outside of trials were systematic-
ally recorded and stored in standard format. Detailed de-
scriptions of patients, treatments and follow-up
modalities have been reported elsewhere [10–14]. In par-
ticular, data for patients suffering IBTR are reported in
ref. [15].
A further database was analysed, including all breast
cancer patients undergoing mastectomy who underwent
delayed reconstructive surgery at Haukeland University
Hospital, Bergen, Norway. The reconstructive proce-
dures were implant surgery, implants combined with
flaps, deep inferior epigastric perforator flaps and trans-
verse rectus abdominis myo-cutaneous flaps. A paired
control was randomly selected from patients with identi-
cal T and N stages, age ± 2 years, and follow-up without
recurrence equal to or longer than the time to recon-
struction of the respective matched reconstructed pa-
tient (defined as “reference time”, i.e. the time origin for
the analysis of DM dynamics for controls). Patient char-
acteristics and details of the study have been reported in
ref. [16]. All studies supplying the analysed databases
were approved by the institutional ethics committees
and review boards in accordance with the Declaration of
Helsinki.
The analysis of recurrence dynamics was focused on
DM as the first event after the second surgery (the
studied timing periods are outlined in Fig. 1): DM-free
survival times were calculated as time elapsed since the
second surgery (for IBTR, CBC or REC) to DM occur-
rence or to the last documented follow-up with no evi-
dence of disease. Second primary tumours, including
contralateral breast cancers, were considered as com-
peting events, and the corresponding event-free
survival times were censored at the time of their occur-
rence. The DM dynamics was studied by estimating
with the life-table method the hazard rate for DM, i.e.
the conditional probability of manifesting DM during a
certain time span, given that the patient is clinically
DM free at the beginning of the interval [17]. A
discretization of the time axis in 6-month units was ap-
plied, and a Kernel-like smoothing procedure [18] was
adopted.
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Results
A CONSORT diagram for IBTR, CBC and REC patients
and matched controls is reported in Fig. 2.
Among patients undergoing conservative surgery, 92%
received chest wall radiation therapy, mostly at the total
dose of 50 Gy (daily dose 2 Gy) with high energy plus 10
Gy (daily dose 2 Gy) as a boost with orthovoltage to the
ipsilateral breast. Following the diagnosis of IBTR or
CBC, the treatment was decided on an individual basis.
Median follow-up times after IBTR and after CBC were
151 months and 144 months, respectively. The number
of patients suffering DM diagnosis within 10 years from
IBTR and CBC was 138 and 84, respectively.
In the Norwegian study, the matched control group in-
cluded patients who were extracted from a total of 868 (see
the “Patients and Methods” section in ref. [16]). Median
follow-up after reconstruction or reference time for con-
trols was 137months. The number of patients suffering
DM within 10 years for REC and controls was 44 and 45,
respectively.
Main patient characteristics at primary tumour treat-
ment are reported in Table 1. In spite of the wide time
span of patient accrual, the homogeneity of main prog-
nostic factors across the databases, with the exception of
tumour size in REC patients, is noteworthy. Axillary
node involvement is near identical, as well as the fre-
quency of ER-positive and ER-negative tumours among
assessed ones, despite the fact that ER content was mea-
sured at different frequencies in the three series. Any-
way, the DM dynamics of ER+ and ER− cancer have
similar timing pattern [19] and, therefore, no modifica-
tion of surgery effects on the time patterns was expected
by oestrogen receptor levels. Moreover, as analysed pa-
tients suffering IBTR and CBC did not receive adjuvant
endocrine therapy just like 42% of ER+ reconstructed
patients, the question of whether endocrine therapy may
alter DM patterns in a modern cohort remains open.
HER2 status was not available and, accordingly, no spe-
cific treatment was administered.
The distribution of surgical treatments for IBTR, CBC
or REC during the follow-up subsequent to primary
tumour removal is reported in Fig. 3. Reconstructions
were performed mainly during the first 5 years (median
time 2.5 years) while IBTR removal had a more pro-
tracted distribution (median time 4.3 years) and a struc-
tured pattern [20]. CBC treatments have a steadier
pattern consistent with the notion that the occurrence
of a CBC may be considered a random event not
time-related with primary tumour [21, 22].
The DM dynamics was analysed for the four groups
in a timeframe with t = 0 at second surgery (Figs. 4
and 5 solid lines). Moreover, the influence of the time
elapsed from primary tumour removal to the second
surgical manoeuvre [time to second surgery] on the
hazard rate for DM pattern was investigated as well
(Figs. 4 and 5 dashed lines). The hazard rate pattern is
similar for the three surgical groups with a first major
peak at about 18 months and a second lower one at
about 5 years from the second surgery, although the
three levels of recurrence risk are different. Time to
second surgery is apparently not influential for recon-
structed patients, whereas it changes the first peak
height for the other sets, showing that the influence is
maximal for early re-operations, decreases afterwards
and apparently disappears for time to second surgery
values larger than 2 to 3 years. To ascertain whether
factors known to be influent on the risk level may
drive the described phenomenon, we analysed the
DM dynamics by time to second surgery in IBTR pa-
tients pooled by axillary node status (node positive vs
node negative) and by second surgery extent (mastec-
tomy vs conservative surgery). In all analysed subsets,
the time to second surgery aroused the same hazard
rate pattern, as Fig. 5 exemplifies for the axillary
nodal involvement. A comparison between REC pa-
tients and controls for DM hazard rate pattern is re-
ported in Fig. 6, where the accelerating effect of
surgery on the DM dynamics is quite evident.
Fig. 1 Analysed times: time to second surgery (from primary cancer surgery to surgery for ipsilateral breast tumour recurrence (IBTR), contralateral
breast cancer (CBC) or breast reconstruction (REC)) and time to distant metastasis (from the second surgery to the appearance of distant metastasis)
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Discussion
Our analysis on breast cancer patients undergoing breast
surgery for IBTR, CBC and REC provides two main re-
sults: (1) the DM dynamics following a new breast surgi-
cal manoeuvre performed after primary tumour removal
is similar to the analogous dynamics following primary
tumour removal and (2) the time span between the two
operations is not associated with changes in peak timing;
yet, for IBTR and CBC patients, it is related to progres-
sive reduction of DM risk levels, while REC patients dis-
play similar DM risk levels for all time spans.
It should be emphasized that the three surgeries are per-
formed in different clinical situations. Surgery for IBTR is
strictly related to the specific multimodal dynamics of
IBTR appearance [15] while CBC diagnosis and
subsequent removal is an independent event with steady
hazard rate [21, 22] and, finally, REC surgery is related to
the patient’s desire and only indirectly to clinical condi-
tions. Therefore, when comparative analyses among pa-
tients with such different tumour-host settings at the time
of surgery display similar behaviours, they are reasonably
attributable to the act of treatment per se. Our findings
suggest that there is a metastasis-enhancing effect in all
surgical interventions, which displays, however, different
traits related to whether a macroscopic breast tumour is
removed or not.
The enhancing effect of surgical primary tumour re-
moval on metastatic disease is well supported by a long
history of investigations [6] and from a few clinical stud-
ies in humans (e.g. [23]). It enables to explain the
Fig. 2 A CONSORT diagram for IBTR, CBC, REC and control patients. Analysed data were from trials carried out between 1975 and 1990 (IBTR,
CBC) and between 1977 and 2007 (REC, controls)
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multipeak pattern of the hazard rate for recurrence in
patients with early breast cancer undergoing surgery or
surgery plus adjuvant chemotherapy [7]. Here, we con-
firm that this enhancing effect is observable even when
surgical manoeuvres are performed in the breast area at
a later date. The result of our analysis apparently
diverges from the outcome of a previous investigation
on the same subject [24] suggesting that traumas or
intervening surgical procedures unrelated to cancer are
not associated with an increased cumulative rate of
breast cancer recurrence in a 2-year window. Although
this discrepancy may be related to the shortness of the
Table 1 Patient characteristics
IBTR (338) CBC (239) Rec (312) Controls (312)
Median age at diagnosis (years) 45 48 48 49
25%–75% 39–52 42–56 42–53 43–53
Range 21–69 22–75 29–73 28–71
Tumour size (%)
T1 85 84 61 62
T2 12 15 29 30
T3/4 – – 8 7
Missing 3 1 2 1
Node negative (%) 70 64 68 67
Node positive (%) 30 36 32 33
ER negative (%) 16 16 20 19
ER positive (%) 63 53 70 70
ER missing (%) 21 31 10 11
Fig. 3 Distribution of surgical treatments for IBTR (red line), CBC (fuchsia line) and reconstruction (blue line) during the follow-up with t = 0 at
primary tumour removal. RECs were performed mainly during the first 5 years (median time 2.5 years) while IBTR removal had a more protracted
distribution (median time 4.3 years) and CBCs had a steadier pattern consistent with the notion that the occurrence of a CBC may be considered
a random event
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analysed interval, a subtler inference could be consid-
ered on the basis of the known topological specificity of
cell populations [25, 26] and of the finding that, in an
animal model, acceleration in tumour growth by
mobilization of bone marrow-derived cells may be dif-
ferent after operative injuries to different organs [27]. In-
deed, one could speculate that surgery in the breast area
may stimulate distant breast cancer foci, unlike surgery
in other sites. Unfortunately, this hypothesis cannot be
disentangled since data on non-breast interventions
were not available for comparison.
Of note, the hazard rate peaks, in particular the first
one, have different heights in IBTR, CBC and REC (Fig. 4).
This occurrence is in keeping with the notion that the
sudden acceleration of metastasis development takes ac-
tion on the underlying DM dynamics, which is different in
IBTR, CBC and REC patients. Indeed, patients with IBTR
have an intrinsic high risk of DM (similar to N+ patients)
that was unpredictable by the usual prognostic factors at
the initial treatment and that is revealed when IBTR
emerges in advance of the competing DM events [15, 28].
In comparison with these patients, women suffering CBC
display a considerably lower first hazard rate peak (about
60% peak to peak) in keeping with the concept that CBC
is a second primary, unrelated to the first one [21, 29, 30].
Accordingly, patients with CBC actually fit to a population
with “average” DM risk [31]. Finally, patients undergoing
REC have better prognosis due to favourable selection cri-
teria: they had no previous recurrence event and factors
such as smoking, obesity and diabetes excluded patients
from being offered complex breast reconstructive proce-
dures. Moreover, the baseline risk in this population may
be influenced by features here not accounted for, such as
socioeconomic conditions, better general health and low
body mass index, which is recently emerging as a prog-
nostic factor in breast cancer [32].
Fig. 4 Distant metastasis dynamics following surgery for IBTR, contralateral breast tumour and reconstruction (t = 0 at second surgery). The hazard
rate pattern is similar for the three groups with a first major peak at about 24 months and a second lower one at about 5 years. The analysis was
performed for all patients (bold lines) and, moreover, by time from primary tumour removal to second surgery as well (dashed lines). While this
factor is not influent for reconstructed patients, it changes the first peak height for surgeries removing neoplastic nodules if the time to second
surgery is less than about 3 years. Confidence intervals on the estimated hazard rates at the first peak position are reported for all patients and
those with time to second surgery more than 48. Y-axis reports hazard rates for DM, i.e. the conditional probability of manifesting DM during an
interval of 6 months, given that the patient is clinically DM free at the beginning of the interval. X-axis units are months between primary tumour
removal and the second surgical manoeuvre
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While there is a substantial body of evidence indicat-
ing that the surgery-associated tissue trauma and wound
healing can promote growth, angiogenesis and meta-
static ability of cancers [33], data on the possible homeo-
static connection between primary tumour and its
metastases are lacking. Our finding that the time to sec-
ond surgery is influential on the risk level only for IBTR
and CBC patients and not for REC patients suggests that
tumour removal, which occurs in the former groups
only, plays a specific role on metastasis development.
This idea is in agreement with the recalled model of
breast cancer metastatic development [7] if one takes
into account that the manifestation of IBTR or CBC, i.e.
of a macroscopic breast tumour, is preceded by a num-
ber of months of subclinical disease. According to the
tumour homeostasis concept [7], during this time span,
the growing tumour exerts constraints on distant micro-
scopic foci, somehow mimicking the homeostatic pro-
cesses underlying the control of size in adult organs and
organisms [34, 35]. Although the molecular characteris-
tics of these mechanisms are largely unknown, recent re-
ports have provided initial interesting findings [36, 37],
which may have oncological important implications as
well [38].
In patients suffering IBTR or CBC, a number of meta-
static foci are related to the previous breast cancer, al-
though a few of them may be associated with the new
breast neoplastic lump. The emerging restrictive inter-
ference results into some freeze of the microscopic
metastases in the conditions existing when the new
homeostatic action is starting. Taking into account the
hazard rate dynamics for the DM related to the primary
breast cancer [7], such a freeze should have effects de-
pending on time to second surgery: the shorter this time,
the higher the underlying DM risk. Consequently, while
the DM dynamics after the IBTR or CBC removal main-
tains the usual time-related pattern, the corresponding
hazard rate level would depend on time to second sur-
gery. Following 2 to 3 years, the time to second surgery
loses its prognostic value, in keeping with the drop of
DM risk attributable to the primary breast cancer [7].
The finding that patients undergoing REC do not
present any effect from the time to second surgery, while
displaying the usual time-related pattern in the
post-reconstruction DM dynamics, suggests that the re-
constructive surgical manoeuvre, in the absence of any
breast tumour removal, may act on metastasis develop-
ment differently from IBRT and CBC surgical removal.
As a working hypothesis, it may be assumed that surgi-
cal manoeuvres prominently act on the microenviron-
ment of tumour foci turning it into conducive (e.g. by
activating angiogenesis) and thus sustaining growth [39].
This facilitating action would simply speed up the clin-
ical appearance of some metastases that would emerge
later according to their own dynamics. This hypothesis
is suggested by the comparison between the hazard rate
patterns for DM in REC patients and in the matched
paired control group (Fig. 6). This comparison suggests
Fig. 5 Distant metastasis dynamics following surgery for IBTR (t = 0 at IBTR) in patients with axillary node positive (left) or negative (right). The
analysis was performed for all patients and, moreover, by time from primary tumour removal to surgery for IBTR. While nodal status affects the
risk level, which is higher for node-positive patients, the time to surgery for IBTR is still influential on the first peak height if it is less than about 3
years. Y-axis reports hazard rates for DM, i.e. the conditional probability of manifesting DM during an interval of 6 months, given that the patient
is clinically DM free at the beginning of the interval. X-axis units are months between primary tumour removal and the second
surgical manoeuvre
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that the reconstruction is associated with a decrease of
the hazard rate for DM at the fourth year and a con-
comitant increase of the hazard rate at the second year.
The present findings are coherent with and integrate
the evidence coming from separate studies on IBTR and
REC, resorting to advanced time scale statistical model-
ling [16, 40]. The overall picture provided support to the
biological hypothesis, underlying the observed distant
metastasis dynamics following surgeries performed after
primary breast cancer surgical removal, according to
different tumour homeostasis-related and surgical
wound-related effects on metastasis development.
The analysed databases did not included data on
HER2, preventing investigations on triple-negative
patients. Moreover, we could not analyse the possible
role of anaesthetic management, which potentially
influences the long-term outcome most probably in
patients undergoing more extended surgery [41], due
to missing information about this factor.
Conclusions
In summary, the findings of the present analysis support
the concept that the impact of breast tumour surgical
removal (either primary or IBTR or CBC) on micro-
scopic metastases is twofold, inasmuch as two different
factors, i.e. tumour homeostasis interruption and surgi-
cal wound effects, are involved. The removal of a breast
tumour would result into the sudden elimination of
the restrains on metastatic foci, thus allowing metas-
tasis development, which, in turn, would be supported
by the forwarding action of the mechanisms triggered
by the surgical wounding. This surgery-related
phenomenon would underlie the behaviour of DMs in
the REC group, where no detectable tumour deposit
is removed. While associations of such latter
phenomenon with surgical-related inflammatory con-
ditions and different anaesthesia modalities are sug-
gested from a few clinical data [41–43], the biological
mechanisms underlying tumour homeostasis are
largely unknown. Investigations in this field are
urgently warranted.
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